EQL Pharma AB (publ) (FRA:7JK)

Market Cap	62.90M -72.6%
Revenue (ttm)	39.43M +15.8%
Net Income	1.14M -70.9%
EPS	0.04 -70.8%
Shares Out	n/a
PE Ratio	55.05
Forward PE	29.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.035
Previous Close	2.125
Day's Range	1.968 - 2.035
52-Week Range	1.968 - 8.800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 60
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7JK

Financial Performance

In fiscal year 2026, EQL Pharma AB's revenue was 432.66 million, an increase of 15.83% compared to the previous year's 373.52 million. Earnings were 12.54 million, a decrease of -70.93%.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error